Press Releases

Date Title and Summary View
Feb 29, 2016
MacroGenics Provides Update on Corporate Progress and 2015 Financial Results
Eight molecules in clinical development, including six in immuno-oncology  Multi-national Phase 1b/2 gastric cancer study initiated evaluating the combination of margetuximab and pembrolizumab  Strong balance sheet supports continued advancement of pipeline
Additional Formats
Feb 16, 2016
MacroGenics Announces Date of Fourth Quarter and Full Year 2015 Financial Results Conference Call
ROCKVILLE, Md., Feb. 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Feb 04, 2016
MacroGenics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Rockville, Md., Feb. 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Dec 02, 2015
MacroGenics to Present at the Oppenheimer 26th Annual Healthcare Conference
ROCKVILLE, Md. , Dec. 02, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Nov 07, 2015
Data from MacroGenics' Ongoing Phase 1 Study of Enoblituzumab (MGA271) Presented at 30th Annual SITC Meeting 2015
Anti-B7-H3 antibody is well-tolerated Single-agent, anti-tumor activity observed across several tumor types Initial evidence of T-cell immunomodulatory role ROCKVILLE, Md. , Nov. 07, 2015 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on
Additional Formats
Nov 05, 2015
Publication in PLOS Pathogens Shows the Potential of DART® Molecules for HIV Reservoir Elimination Strategy
Second paper published demonstrating DART molecule potential against HIV Data support HIV research contract recently awarded to MacroGenics by NIAID ROCKVILLE, Md. , Nov. 05, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering
Additional Formats
Nov 04, 2015
MacroGenics Provides Update on Corporate Progress and Third Quarter 2015 Financial Results
Bi-specific antibody leadership — fifth DART® molecule (MGD009) enters clinical testing B7-H3 franchise advances — Encouraging initial clinical results from ongoing enoblituzumab (MGA271) Phase 1 trial and regional rights regained  Recent collaboration with Merck on immuno-oncology study evaluating
Additional Formats
Nov 04, 2015
MacroGenics to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md. , Nov. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Oct 28, 2015
MacroGenics Announces Date of Third Quarter 2015 Financial Results Conference Call
Rockville, MD , Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 4, 2015 , the Company will release its financial results for the quarter ended September 30, 2015 . The Company's management team will host a conference call discussing the
Additional Formats
Oct 28, 2015
MacroGenics Regains European and Other Regional Rights to Enoblituzumab
Servier does not exercise option to license rights for enoblituzumab in its specified territories MacroGenics advances enoblituzumab and pursues integrated B7-H3 franchise strategy Rockville, MD , Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage
Additional Formats
Oct 22, 2015
MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA(R) (pembrolizumab) for Advanced Gastric Cancer

Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer

Additional Formats
Oct 13, 2015
MacroGenics Highlights Progress at 2015 R&D Day
Encouraging initial clinical results from ongoing enoblituzumab (MGA271) trial B7-H3 franchise extended — fifth DART® molecule (MGD009) in Phase 1 Proprietary immune checkpoint PD-1 x LAG-3 DART molecule (MGD013) introduced HIV DART and Trident™ tri-specific platform introduced ROCKVILLE, Md.
Additional Formats
Oct 06, 2015
MacroGenics to Host 2015 R&D Day

--Company to provide in-depth review of its antibody-based technology platforms and broad portfolio of therapeutics being developed to treat cancer, autoimmune disorders and infectious diseases

Additional Formats
Oct 01, 2015
MacroGenics Announces Presentation at 30th Annual SITC Meeting 2015
ROCKVILLE, Maryland , Oct. 01, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Sep 22, 2015
MacroGenics to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md. , Sept. 22, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Sep 03, 2015
MacroGenics to Participate in Two Upcoming Investor Conferences
MacroGenics to Participate in Two Upcoming Investor Conferences ROCKVILLE, Md., Sept. 03, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of
Additional Formats
Aug 05, 2015
MacroGenics Provides Update on Corporate Progress and Second Quarter 2015 Financial Results
-- Fourth bi-specific DART® molecule, MGD011, in clinical testing         -- Margetuximab Phase 3 SOPHIA metastatic breast cancer study initiated         -- Balance sheet strengthened with completion of $141 million equity offering ROCKVILLE, Md. , Aug.
Additional Formats
Aug 04, 2015
MacroGenics to Present at the 2015 Wedbush PacGrow Healthcare Conference
Rockville, MD , Aug. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Jul 29, 2015
MacroGenics Announces Date of Second Quarter 2015 Financial Results Conference Call
ROCKVILLE, Md , July 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 5, 2015 , the Company will release its financial results for the quarter ended June 30, 2015 . The Company's management team will host a conference call discussing the
Additional Formats
Jul 28, 2015
MGD011 Advances Into Clinical Development
—  Triggers $10 million milestone payment from Janssen  —  Fourth DART® molecule to enter the clinic in last 12 months ROCKVILLE, Md. , July 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc.  (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative
Additional Formats
Jul 14, 2015
MacroGenics Announces Pricing of Public Offering of Common Stock
ROCKVILLE, Md. , July 14, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Jul 13, 2015
MacroGenics Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md. , July 13, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
May 30, 2015
MacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO Annual Meeting 2015

Data Show Signs of Clinical Activity for Margetuximab in HER2-Expressing Tumors

Additional Formats
May 27, 2015
MacroGenics Preclinical Research on MGD006 DART(R) Molecule Published in Science Translational Medicine
—    MGD006 Enables T Cells to Recognize and Kill Leukemia Cells —     Research Paved the Way for Human Clinical Trials ROCKVILLE, Md. , May 27, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative
Additional Formats
May 13, 2015
MacroGenics Announces Presentation at ASCO Annual Meeting 2015

Company to Present Updated Findings From Its Phase 1 Study of Margetuximab

Additional Formats